Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

Sunday, Sanofi SA’s (NASDAQ:SNY) data from the HERCULES phase 3 study showed that tolebrutinib met the primary endpoint of ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

But tolebrutinib showed something novel at ECTRIMS. In the phase III HERCULES trial, tolebrutinib slowed confirmed disability ...

Sanofi said the GEMINI 1 and 2 trials of tolebrutinib in relapsing forms of MS are fully enrolled and should read out in time to meet its plan of filing for regulatory approval in the US in 2024.

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

But because we don’t know what’s driving it, we don’t know what to go after.” The study was supported by Sanofi. Cree is a co ...

Phase 3 trial results Tolebrutinib (Sanofi) Bruton tyrosine kinase inhibitor Treatment of non-relapsing secondary progressive multiple sclerosis. Phase 3 trial results Depemokimab (GSK ...

The recent results of tolebrutinib in non-active secondary progressive MS presented at the ECTRIMS 2024 conference, reinforce the scientific hypothesis that targeting microglia in nSPMS is a valid ...

A key focus will be the results from large phase 3 trials of BTK inhibitors such as tolebrutinib, which are eagerly anticipated by the MS community. Additionally, there may be discussions on ...

It's the first anti-CD38 with this data in this setting. Finally, we've shared several positive Phase 3 readouts, including tolebrutinib, one of our BTK inhibitors, which is notable for its effect ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...